ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.

Menu